Table 2.
Glycan profiles of the anti-tetanus mAbs.
| Glycan | TT-117 | TT-120 | TT-140 | TT-143 | TT-243 |
|---|---|---|---|---|---|
| SA | -- | 4.28 | 2.91 | -- | 2.76 |
| A2 | 7.70 | 9.34 | 5.69 | 22.35 | 8.88 |
| A2F | 3.20 | 7.19 | 5.92 | 10.51 | 5.93 |
| Mn5 | 3.90 | 3.51 | 9.17 | 3.37 | 3.17 |
| G0 | 3.72 | 4.04 | 3.80 | 3.83 | 4.11 |
| G0F | 64.02 | 52.44 | 53.58 | 44.00 | 56.93 |
| G1/G1′ | -- | -- | -- | 1.41 | 0.46 |
| G1F/G1F’ | 7.04 | 5.97 | 4.49 | 3.16 | 4.45 |
| G2 | 2.04 | 2.35 | 3.69 | -- | 1.01 |
| G2F | 0.54 | 0.68 | 3.37 | -- | -- |
| Fucosylated | 74.80 | 66.27 | 67.36 | 57.66 | 67.30 |
| Galactosylated | 9.62 | 9.00 | 11.55 | 4.57 | 5.91 |
| Sialyted | 10.90 | 20.81 | 14.52 | 32.85 | 17.57 |
| High mannose | 3.90 | 3.51 | 9.17 | 3.37 | 3.17 |
The glycan proportion was analyzed for each mAb.